Sheet 1 of 1 SERIAL NO ATTY DOCKET N APPLICANT FACSIMILE OF FORM PTO-1449 **GNN-009CP** 09/772,103 LIST OF PUBLICATIONS CITED BY APPLICANT Carreno, Beatriz M. et al. (Use several sheets if necessary) 1645 January 26, 2001 0 2 2002 **U.S. PATENT DOCUMENTS** SUBCLASS CLASS EXAMINER NICE DOCUMENT NUMBER DATE FOREIGN PATENT DOCUMENTS SUBCLASS TRANSLATION CLASS DOCUMENT NUMBER DATE NO YES PCT 12/98 A1 WO 98/56417 A JUL OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) Colombatti, M. et al., "Selective killing of target cells by antibody-ricin A chain or antibody-gelonin hybrid molecules: comparison of cytotoxic potency and use in immunoselection procedures," J. Immunol., 1983 Dec;131(6):3091-5 Duke-Cohan, J. S. et al., "Targeting of an activated T-cell subset using a bispecific antibody-toxin **A**3 conjugate directed against CD4 and CD26," Blood, 1993 Oct 1,82(7):2224-34 Koehler, M. et al., "XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for A4 prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors," Bone Marrow Transplant., 1994 May;13(5):571-5 Razi-Wolf, Ziba et al., "Evidence for an additional ligand, distinct from B7, for the CTLA-4 A5 receptor," Proc. Nat. Acad. Sci. U.S.A., 90(23):11182-6 (1993) Sievers, E.L. et al., "Selective ablation of acute myeloid leukemia using antibody-targeted A6 chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate," Blood 1999 Jun 1:93(11):3678-84 Vandenborre, K. et al., "Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell A7 activation," Immunology, 98(3):413-421 (1999) Mo Date Considered Examiner 7/11/07 Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through \*EXAM/NER:

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.